IGC Pharma’s Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer’s Market May 22, 2025 Read More »
IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting May 12, 2025 Read More »
IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer’s Innovation and AI-Driven Programs April 21, 2025 Read More »
IGC Pharma Expands CALMA Alzheimer’s Phase 2 Trial with Prestigious Research Site at Butler Hospital’s Memory and Aging Program April 8, 2025 Read More »
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health April 1, 2025 Read More »
IGC Pharma’s Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances March 26, 2025 Read More »
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences March 20, 2025 Read More »
IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida March 17, 2025 Read More »
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25” March 12, 2025 Read More »
